Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro

Ji Yao Sun, Robert S Krouse, Stephen J. Forman, David Senitzer, Irena Sniecinski, Saswati Chatterjee, K. K. Wong

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) is characterized by a t(9;22) translocation, which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. As a strategy for the immunotherapy of CML, we constructed a recombinant adeno-associated virus vector encoding the p210BCR-ABL b3a2 variant fusion region with flanking sequences (CWRBA) and used it to express the BCR-ABL fusion region within primary human dendritic cells (DCs), the most potent antigen-presenting cells currently known. Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA, CWRAP (negative control), or pulsed with a peptide corresponding to the fusion domain (positive control). No specific responses were generated using DCs transduced with CWRAP. In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricted fashion to levels comparable with the positive control. CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses, although the former were more readily detected in this system. Cytotoxicity against a tumor cell line endogenously expressing the p210BCR-ABL b3a2 variant fusion region was also demonstrable. In addition, HLA-DRB5*0101+DRA (DR2a) was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope. Thus, the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development.

Original languageEnglish (US)
Pages (from-to)3175-3183
Number of pages9
JournalCancer Research
Volume62
Issue number11
StatePublished - Jun 1 2002
Externally publishedYes

Fingerprint

Dependovirus
DNA Vaccines
Dendritic Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Immunotherapy
HLA-DRB5 Chains
Vaccines
Antigens
Oncogene Proteins
Antigen-Presenting Cells
Tumor Cell Line
In Vitro Techniques
Epitopes
Blood Cells
Carcinogenesis
Clone Cells
T-Lymphocytes
Peptides
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. / Sun, Ji Yao; Krouse, Robert S; Forman, Stephen J.; Senitzer, David; Sniecinski, Irena; Chatterjee, Saswati; Wong, K. K.

In: Cancer Research, Vol. 62, No. 11, 01.06.2002, p. 3175-3183.

Research output: Contribution to journalArticle

Sun, Ji Yao ; Krouse, Robert S ; Forman, Stephen J. ; Senitzer, David ; Sniecinski, Irena ; Chatterjee, Saswati ; Wong, K. K. / Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. In: Cancer Research. 2002 ; Vol. 62, No. 11. pp. 3175-3183.
@article{46c2e5744da2421196e677d4aaf941c9,
title = "Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro",
abstract = "Chronic myelogenous leukemia (CML) is characterized by a t(9;22) translocation, which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. As a strategy for the immunotherapy of CML, we constructed a recombinant adeno-associated virus vector encoding the p210BCR-ABL b3a2 variant fusion region with flanking sequences (CWRBA) and used it to express the BCR-ABL fusion region within primary human dendritic cells (DCs), the most potent antigen-presenting cells currently known. Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA, CWRAP (negative control), or pulsed with a peptide corresponding to the fusion domain (positive control). No specific responses were generated using DCs transduced with CWRAP. In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricted fashion to levels comparable with the positive control. CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses, although the former were more readily detected in this system. Cytotoxicity against a tumor cell line endogenously expressing the p210BCR-ABL b3a2 variant fusion region was also demonstrable. In addition, HLA-DRB5*0101+DRA (DR2a) was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope. Thus, the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development.",
author = "Sun, {Ji Yao} and Krouse, {Robert S} and Forman, {Stephen J.} and David Senitzer and Irena Sniecinski and Saswati Chatterjee and Wong, {K. K.}",
year = "2002",
month = "6",
day = "1",
language = "English (US)",
volume = "62",
pages = "3175--3183",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro

AU - Sun, Ji Yao

AU - Krouse, Robert S

AU - Forman, Stephen J.

AU - Senitzer, David

AU - Sniecinski, Irena

AU - Chatterjee, Saswati

AU - Wong, K. K.

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Chronic myelogenous leukemia (CML) is characterized by a t(9;22) translocation, which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. As a strategy for the immunotherapy of CML, we constructed a recombinant adeno-associated virus vector encoding the p210BCR-ABL b3a2 variant fusion region with flanking sequences (CWRBA) and used it to express the BCR-ABL fusion region within primary human dendritic cells (DCs), the most potent antigen-presenting cells currently known. Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA, CWRAP (negative control), or pulsed with a peptide corresponding to the fusion domain (positive control). No specific responses were generated using DCs transduced with CWRAP. In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricted fashion to levels comparable with the positive control. CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses, although the former were more readily detected in this system. Cytotoxicity against a tumor cell line endogenously expressing the p210BCR-ABL b3a2 variant fusion region was also demonstrable. In addition, HLA-DRB5*0101+DRA (DR2a) was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope. Thus, the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development.

AB - Chronic myelogenous leukemia (CML) is characterized by a t(9;22) translocation, which results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for oncogenesis, unique to the leukemic clones, and represent enticing targets for immunotherapy. As a strategy for the immunotherapy of CML, we constructed a recombinant adeno-associated virus vector encoding the p210BCR-ABL b3a2 variant fusion region with flanking sequences (CWRBA) and used it to express the BCR-ABL fusion region within primary human dendritic cells (DCs), the most potent antigen-presenting cells currently known. Peripheral blood mononuclear cells from healthy donors were primed and restimulated in vitro with autologous DCs transduced with purified CWRBA, CWRAP (negative control), or pulsed with a peptide corresponding to the fusion domain (positive control). No specific responses were generated using DCs transduced with CWRAP. In contrast, CWRBA-transduced DCs primed autologous T cells in an antigen-specific, MHC-restricted fashion to levels comparable with the positive control. CWRBA-transduced DCs elicited both cytotoxic CD4+/Th1 and CD8+ responses, although the former were more readily detected in this system. Cytotoxicity against a tumor cell line endogenously expressing the p210BCR-ABL b3a2 variant fusion region was also demonstrable. In addition, HLA-DRB5*0101+DRA (DR2a) was identified as a new restriction element capable of presenting the b3a2 BCR-ABL fusion region epitope. Thus, the construct developed herein may serve as a candidate vaccine for gene-based antigen-specific immunotherapy of CML and may serve as a paradigm for the use of DCs transduced with recombinant adeno-associated virus vectors encoding multiepitope immunogens for vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=0036605994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036605994&partnerID=8YFLogxK

M3 - Article

C2 - 12036931

AN - SCOPUS:0036605994

VL - 62

SP - 3175

EP - 3183

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -